abbv-257
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02531178)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- TNF-alphaImmunity, passive
TNF immunity, passive
- Interleukin 17AImmunity, passive
IL17A immunity, passive
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSMA59O0RPES ↗
- ChEMBLCHEMBL4297682 ↗
Also known as
- abbv-257
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02531178 | Phase 1 | Jul 1, 2015 | AbbVie |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1